Public neuroscience

Neuroscience is nearly everywhere, and in places where it isn’t, it should be.

NeuRA is committed to communicating its research findings and the implications of these findings to a broad audience. We all have a brain and a nervous system collecting sensory input, controlling our breathing, beating our heart, coordinating our muscles, telling our face when to smile.  Continue reading

How does having dementia affect everyday activities?

A NeuRA study recently investigated how different types of dementia affect the ability to perform everyday tasks. The focus was on progressive nonfluent aphasia (PNFA) and logopenic nonfluent aphasia (LPA) – two dementias that lead to similar problems in language (at least to the untrained ear, not so according to specific language tests). Under the microscope these dementias look very different: PNFA dementia is more closely linked to frontotemporal dementia, and LPA is more closely linked to Alzheimer’s disease. Continue reading

Measuring stroke recovery…wirelessly

Using wireless telemetry we are focussing on studying how and why stroke therapy works, rather than just measuring how effective stroke therapy can be. Wireless telemetry refers to wireless, machine-to-machine communication. In our context, we use wireless telemetry to record physiological signals to measure how the body responds during stroke therapy. Continue reading

Schizophrenia and the immune system, an inflammatory topic

Our new study suggests that we can add schizophrenia to the list of diseases containing an immune system element.  As such, this provides a new set of targets for therapeutic interventions in schizophrenia, which in combination with previous treatments can help alleviate the burden of this disease. You can read the paper here, and the media release here. Continue reading

‘Turning down’ voices and ‘turning up’ thinking in schizophrenia

We are calling for volunteers to take part in a new clinical trial that may help people with schizophrenia.

Many people with schizophrenia have residual symptoms in spite of treatment with antipsychotic medication. Auditory hallucinations (‘hearing voices’) are a symptom that is treatment-resistant in 25 to 30% of patients, and cause distress. Continue reading